Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a study of repeated IT administrations of BO-112 in combination with ablative
radiotherapy (SABR) and concurrent nivolumab in patients with metastatic
PD-1/PD-L1-refractory NSCLC.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Clinica Universidad de Navarra, Universidad de Navarra